CGEM News and Press, Cullinan Therapeutics Inc.

Presentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial, which met its primary endpoint of progression-free survival in first line EGFR exon 20 insertion mutation NSCLC Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) toda...

CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion studies to begin early 2027 Velinotamig (BCMA TCE) multi-dose regimen data in SLE in Q4 2026; Phase 1/2 basket study in autoimmune cytopenias to begin early 2027 CLN-049 (FLT3 TCE) potentiall...

2026-06-11 11:41:04 ET Topline Summary and Update Read the full article on Seeking Alpha For further details see: Cullinan Therapeutics: Heading Toward Paydirt

2026-06-10 17:32:10 ET Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune Diseases June 10, 2026 8:30 AM EDT... Read the full article on Seeking Alpha For further details see: Cullinan Therapeutics, Inc. (CGEM) Disc...

CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) CLN-978 data from the first RA multi-dose regimen cohort demonstrated robust efficacy, including clinical remission in a poly-r...

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978  Deep, dose-dependent B cell depletion observed in peripheral blood and tissue Favorable safety profile wi...

2026-05-28 08:40:06 ET Denver, Colorado ( www.247marketnews.com ) – Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. For emerging biotech companies, Phase 2 is often the moment when science transitions ...

New and updated clinical data to be presented from over 30 patients across systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) studies  Initial data from the first multi-dose cohort of RA study to be presented Initial data from the first multi-dose cohort of velinotamig ...

Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc.  (Nasdaq: CGEM), a clinical-stage biopharmaceutical company acceleratin...

CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc.  (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that initial clinical data fr...